Gossamer Bio's Seralutinib Fails Phase 3 PROSERA PAH Primary Endpoint
Gossamer Bio’s seralutinib failed to meet the primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension, showing no statistically significant improvement after 24 weeks of treatment. The company will analyze full data and assess strategic options for its PAH pipeline.
1. PROSERA Phase 3 Results
Gossamer Bio announced that seralutinib did not achieve its primary endpoint in the PROSERA Phase 3 trial for pulmonary arterial hypertension, with no significant efficacy observed in the treated cohort over 24 weeks of dosing.
2. Company Response and Next Steps
The company plans to complete a detailed review of secondary and exploratory endpoints, evaluate long-term safety and efficacy data, and explore strategic options for the PAH program, including potential collaborations or alternative development pathways.